Internationally Renowned Botulinum Toxin Experts Join WizMedi Bio's New Botulinum Toxin Development Project
26 Abril 2024 - 12:05AM
Dr. Eric A. Johnson and Professor Dirk Dressler, internationally
renowned botulinum toxin experts, visited South Korea in March this
year to join WizMedi Bio's new botulinum toxin development project.
Their involvement is expected to profoundly boost product
development and registration processes.
The long-standing collaboration between Dr.
Johnson and Professor Dressler has shaped the global botulinum
toxin landscape over the past decades. Dr. Johnson, a retired
professor of bacteriology at the University of Wisconsin-Madison in
the US, has dedicated over four decades to botulinum toxin
research, authoring over 200 publications and founded 3 botulinum
toxin companies. His prominent contributions led to the development
of the first botulinum toxin drug.
Professor Dressler, the head of the Movement
Disorders Section at Hannover Medical School in Germany, has been
at the forefront of both translational botulinum toxin research and
the development of all significant clinical applications, including
dystonia, spasticity, migraine, hyperhidrosis, and aesthetic
indications. Having introduced most of the major botulinum toxin
drugs to the international markets, he is a highly sought-after
consultant to the botulinum toxin industry.
WizMedi Bio recently announced the acquisition
of the exclusive rights to the newly developed and patented
botulinum toxin type A6 strain from the Wisconsin Alumni Research
Foundation(WARF), a subsidiary of the University of Wisconsin.
Related link:
https://www.linkedin.com/posts/wisconsin-alumni-research-foundation_home-activity-7180994912107028482-7NPo/
During their visit to Korea, Dr. Johnson and
Professor Dressler visited BNC Korea's cutting-edge manufacturing
and research facilities, solidifying the positive outlook for the
project's success. BNC Korea and WizMedi Bio formed a strategic
partnership in 2023 to research and develop new botulinum toxin
products.
Dr. Johnson expressed his enthusiasm by saying:
" I am excited about the novelty of A6 botulinum toxin and its
potential as a new drug in the growing botulinum field. My visit to
WizMedi Bio and their professionalism has only strengthened my
confidence in this project."
Dr. Yonghun Choi, the CEO of WizMedi Bio, said:
"The two experts are already mythical figures in the botulinum
toxin arena, and it is an absolute delight for us to work with both
of them simultaneously. We look forward to working with them to
bring our new potent A6 toxin to the market as soon as
possible."
Social Links
Twitter: https://twitter.com/WIZMEDIKR
Media Contact
Company: Wizmedi Co., Ltd.
Contact: Media Team
Email: marketing@wizmedi.kr
Website: https://wizmedi.kr
SOURCE: Wizmedi Co., Ltd.